Pages that link to "Q87609508"
Jump to navigation
Jump to search
The following pages link to Belinostat: first global approval (Q87609508):
Displaying 29 items.
- HDAC and HDAC Inhibitor: From Cancer to Cardiovascular Diseases (Q26766640) (← links)
- Panoptic clinical review of the current and future treatment of relapsed/refractory T-cell lymphomas: Peripheral T-cell lymphomas (Q26774771) (← links)
- Belinostat in patients with refractory or relapsed peripheral T-cell lymphoma: a perspective review (Q26796449) (← links)
- Epigenetic modulators as therapeutic targets in prostate cancer (Q28071912) (← links)
- Histone deacetylase inhibitors in clinical studies as templates for new anticancer agents (Q35214924) (← links)
- Redox-Mediated Suberoylanilide Hydroxamic Acid Sensitivity in Breast Cancer (Q35822102) (← links)
- Epigenetic activities of flavonoids in the prevention and treatment of cancer (Q35835175) (← links)
- Synergistic anti-leukemic interactions between panobinostat and MK-1775 in acute myeloid leukemia ex vivo (Q36843733) (← links)
- Histone Deacetylase Inhibitors Delivery using Nanoparticles with Intrinsic Passive Tumor Targeting Properties for Tumor Therapy (Q36882942) (← links)
- Fingerprinting of neurotoxic compounds using a mouse embryonic stem cell dual luminescence reporter assay (Q37578338) (← links)
- Belinostat for Relapsed or Refractory Peripheral T-Cell Lymphoma. (Q37579991) (← links)
- Metal-dependent Deacetylases: Cancer and Epigenetic Regulators (Q38747135) (← links)
- HDAC8 substrate selectivity is determined by long- and short-range interactions leading to enhanced reactivity for full-length histone substrates compared with peptides. (Q47434218) (← links)
- WMJ-8-B, a novel hydroxamate derivative, induces MDA-MB-231 breast cancer cell death via the SHP-1-STAT3-survivin cascade (Q48227330) (← links)
- Molecular, biological characterization and drug sensitivity of chidamide-resistant non-small cell lung cancer cells (Q48533275) (← links)
- HDAC inhibitor PAC-320 induces G2/M cell cycle arrest and apoptosis in human prostate cancer (Q49813665) (← links)
- A Novel Hydroxamate-Based Compound WMJ-J-09 Causes Head and Neck Squamous Cell Carcinoma Cell Death via LKB1-AMPK-p38MAPK-p63-Survivin Cascade (Q51739539) (← links)
- Oxazole-Bridged Combretastatin A-4 Derivatives with Tethered Hydroxamic Acids: Structure⁻Activity Relations of New Inhibitors of HDAC and/or Tubulin Function (Q61814436) (← links)
- Revisiting Histone Deacetylases in Human Tumorigenesis: The Paradigm of Urothelial Bladder Cancer (Q64039896) (← links)
- The ROMP: A Powerful Approach to Synthesize Novel pH-Sensitive Nanoparticles for Tumor Therapy (Q64242853) (← links)
- Histone Deacetylases (HDACs) Guided Novel Therapies for T-cell lymphomas (Q64274976) (← links)
- Targeting HDAC/OAZ1 axis with a novel inhibitor effectively reverses cisplatin resistance in non-small cell lung cancer (Q64283583) (← links)
- Development of hydroxamate-based histone deacetylase inhibitors of bis-substituted aromatic amides with antitumor activities (Q90380896) (← links)
- Epigenetic Regulation of MDR1 and BCRP Transporters by HDAC Inhibition (Q90470355) (← links)
- Metabolism and Pharmacokinetic Study of the Boron-Containing Prodrug of Belinostat (ZL277), a Pan HDAC Inhibitor with Enhanced Bioavailability (Q91816989) (← links)
- Synthesis and Biological Evaluation of HDAC Inhibitors With a Novel Zinc Binding Group (Q94465671) (← links)
- Multitarget inhibition of histone deacetylase (HDAC) and phosphatidylinositol-3-kinase (PI3K): Current and future prospects (Q100529887) (← links)
- Novel Pyridine-Based Hydroxamates and 2'-Aminoanilides as Histone Deacetylase Inhibitors: Biochemical Profile and Anticancer Activity (Q102317286) (← links)
- A `one-two punch' therapy strategy to target chemoresistance in estrogen receptor positive breast cancer (Q102320144) (← links)